Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0392 Transporter Info
Gene Name	SLC51B
Transporter Name	Organic solute transporter subunit beta
Gene ID	123264
UniProt ID	Q86UW2

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ethinyl Estradiol co-treated with Cholic Acids affects the expression of SLC51B mRNA			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Calcitriol co-treated with Chenodeoxycholic Acid results in decreased expression of SLC51B mRNA			[8]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cisplatin co-treated with jinfukang results in increased expression of SLC51B mRNA			[14]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cyclosporine co-treated with Cholic Acids affects the expression of SLC51B mRNA			[32]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine results in increased expression of SLC51B mRNA			[10]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Triclosan results in increased expression of SLC51B mRNA			[56]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC51B 5' UTR			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in increased expression of SLC51B mRNA			[21]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Benzo(a)pyrene results in increased methylation of SLC51B exon			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Benzo(a)pyrene results in increased methylation of SLC51B promoter			[39]
Regulation Mechanism				Transcription Factor Info
1-Naphthylisothiocyanate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Naphthylisothiocyanate co-treated with Cholic Acids affects the expression of SLC51B mRNA			[32]
Regulation Mechanism				Transcription Factor Info
2,4,5,2',4',5'-hexachlorobiphenyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2,4,5,2',4',5'-hexachlorobiphenyl affects the expression of SLC51B mRNA			[33]
Regulation Mechanism				Transcription Factor Info
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of SLC51B mRNA			[34]
Regulation Mechanism				Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	abrine results in decreased expression of SLC51B mRNA			[35]
Regulation Mechanism				Transcription Factor Info
Asbestos, Serpentine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Asbestos, Serpentine results in increased expression of SLC51B mRNA			[37]
Regulation Mechanism				Transcription Factor Info
Atazanavir Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A affects the expression of SLC51B mRNA			[28]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC51B gene			[41]
Regulation Mechanism				Transcription Factor Info
Chenodeoxycholic Acid	12 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Calcitriol co-treated with Chenodeoxycholic Acid results in decreased expression of SLC51B mRNA			[8]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Chenodeoxycholic Acid results in increased expression of SLC51B mRNA			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Chenodeoxycholic Acid results in increased expression of SLC51B protein			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	epigallocatechin gallate inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51B mRNA			[44]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	NR1H4 mutant form inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51B mRNA			[4]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	NR1H4 protein affects the reaction Chenodeoxycholic Acid results in increased expression of SLC51B mRNA			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
Chlorpromazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorpromazine co-treated with Cholic Acids affects the expression of SLC51B mRNA			[32]
Regulation Mechanism				Transcription Factor Info
DEET	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	fipronil co-treated with DEET results in increased expression of SLC51B mRNA			[25]
Regulation Mechanism				Transcription Factor Info
Deoxycholic Acid	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Deoxycholic Acid results in increased expression of SLC51B			[45]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Deoxycholic Acid results in increased expression of SLC51B mRNA			[12]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
epigallocatechin gallate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	epigallocatechin gallate inhibits the reaction Chenodeoxycholic Acid results in increased expression of SLC51B mRNA			[44]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	epigallocatechin gallate inhibits the reaction GW 4064 results in increased expression of SLC51B mRNA			[44]
Regulation Mechanism				Transcription Factor Info
fipronil	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	fipronil co-treated with DEET results in increased expression of SLC51B mRNA			[25]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	fipronil results in increased expression of SLC51B mRNA			[25]
Regulation Mechanism				Transcription Factor Info
Glycochenodeoxycholic Acid	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
Glycocholic Acid	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC51A protein binds to SLC51B protein which results in increased uptake of Glycocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
Glycodeoxycholic Acid	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[42]
Regulation Mechanism				Transcription Factor Info
GW 4064	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	epigallocatechin gallate inhibits the reaction GW 4064 results in increased expression of SLC51B mRNA			[44]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	GW 4064 results in increased expression of SLC51B mRNA			[44]
Regulation Mechanism				Transcription Factor Info
Methyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyl Methanesulfonate results in decreased expression of SLC51B mRNA			[23]
Regulation Mechanism				Transcription Factor Info
Methyltestosterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyltestosterone co-treated with Cholic Acids affects the expression of SLC51B mRNA			[32]
Regulation Mechanism				Transcription Factor Info
NCS 382	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	NCS 382 results in increased expression of SLC51B mRNA			[48]
Regulation Mechanism				Transcription Factor Info
nefazodone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in increased expression of SLC51B mRNA			[38]
Regulation Mechanism				Transcription Factor Info
obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	obeticholic acid results in increased expression of SLC51B mRNA			[15]
Regulation Mechanism				Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in increased expression of SLC51B mRNA			[49]
Regulation Mechanism				Transcription Factor Info
Oxygen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Oxygen deficiency results in increased expression of SLC51B mRNA			[4]
Regulation Mechanism				Transcription Factor Info
Pantothenic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pantothenic Acid results in increased expression of SLC51B mRNA			[7]
Regulation Mechanism				Transcription Factor Info
perfluorobutanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorobutanesulfonic acid			[50]
Regulation Mechanism				Transcription Factor Info
perfluorohexanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorohexanesulfonic acid			[50]
Regulation Mechanism				Transcription Factor Info
perfluorooctanesulfonamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctanesulfonamide results in decreased expression of SLC51B mRNA			[51]
Regulation Mechanism				Transcription Factor Info
perfluorooctane sulfonic acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctane sulfonic acid results in increased expression of SLC51B mRNA			[19]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC51A protein binds to SLC51B protein which results in increased transport of perfluorooctane sulfonic acid			[50]
Regulation Mechanism				Transcription Factor Info
perfluorooctanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctanoic acid results in increased expression of SLC51B mRNA			[19]
Regulation Mechanism				Transcription Factor Info
pirinixic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pirinixic acid binds to and results in increased activity of PPARA protein which results in increased expression of SLC51B mRNA			[52]
Regulation Mechanism				Transcription Factor Info
resorcinol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	resorcinol results in decreased expression of SLC51B mRNA			[22]
Regulation Mechanism				Transcription Factor Info
Silicon Dioxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Silicon Dioxide analog results in decreased expression of SLC51B mRNA			[54]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC51B mRNA			[26]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	sodium arsenite results in increased expression of SLC51B mRNA			[55]
Regulation Mechanism				Transcription Factor Info
Taurochenodeoxycholic Acid	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
Taurocholic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC51A protein binds to SLC51B protein which results in increased uptake of Taurocholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
Tetrachlorodibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetrachlorodibenzodioxin results in decreased expression of SLC51B mRNA			[10]
Regulation Mechanism				Transcription Factor Info
Triiodothyronine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction Triiodothyronine results in increased expression of SLC51B mRNA			[11]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Triiodothyronine results in increased expression of SLC51B mRNA			[11]
Regulation Mechanism				Transcription Factor Info
tris(2-butoxyethyl) phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tris(2-butoxyethyl) phosphate affects the expression of SLC51B mRNA			[57]
Regulation Mechanism				Transcription Factor Info
troglitazone sulfate	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Glycochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	troglitazone sulfate inhibits the reaction SLC51A protein binds to SLC51B protein which results in increased uptake of Taurochenodeoxycholic Acid			[46]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Fidaxomicin	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fidaxomicin inhibits the transportation of Dehydroepiandrosterone sulfate by SLC51B (IC50 < 200 microM)			[1]
Affected Drug/Substrate	Dehydroepiandrosterone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
DT Modulation2	Fidaxomicin inhibits the activity of SLC51B			[2]
Ethinyl Estradiol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ethinyl estradiol inhibits the transportation of Dehydroepiandrosterone sulfate by SLC51B (IC50 < 200 microM)			[1]
Affected Drug/Substrate	Dehydroepiandrosterone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Troglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Troglitazone inhibits the transportation of Dehydroepiandrosterone sulfate by SLC51B (IC50 < 200 microM)			[1]
Affected Drug/Substrate	Dehydroepiandrosterone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Digoxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Digoxin inhibits the transportation of Estrone sulfate by SLC51B (IC50 < 500 microM)			[]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Indomethacin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Indomethacin inhibits the transportation of Estrone sulfate by SLC51B (IC50 = 200 microM)			[]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Spironolactone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Spironolactone inhibits the transportation of Estrone sulfate by SLC51B (IC50 > 200 microM)			[]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Cholic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cholic Acid increases the expression of SLC51B			[3]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	Mouse colon adenocarcinoma cells (CT26)
Deoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Deoxycholic acid increases the expression of SLC51B			[4]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	Human adult hepatocellular carcinoma cells (Huh7)
Chenodeoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic acid increases the expression of SLC51B			[4]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	Human adult hepatocellular carcinoma cells (Huh7)
Rifampin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampin increases the expression of SLC51B			[5]
Regulation Mechanism	via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2)			Transcription Factor Info
Cell System	Human hepatocytes
Phenobarbital	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenobarbital increases the expression of SLC51B			[6]
Pantothenate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pantothenate increases the expression of SLC51B			[7]
Budesonide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Budesonide increases the expression of SLC51B			[8]
Calcitriol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Calcitriol inhibits the expression of SLC51B			[8]
Dexamethasone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dexamethasone increases the expression of SLC51B			[8]
Hydrogen Peroxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydrogen Peroxide affects the expression of SLC51B			[9]
Estradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol increases the expression of SLC51B			[10]
Liothyronine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Liothyronine increases the expression of SLC51B			[11]
Ursodeoxycholic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ursodeoxycholic Acid increases the expression of SLC51B			[12]
Rosiglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rosiglitazone increases the expression of SLC51B			[13]
Cisplatin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cisplatin increases the expression of SLC51B			[14]
Obeticholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Obeticholic acid increases the expression of SLC51B			[15]
Leflunomide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Leflunomide increases the expression of SLC51B			[16]
Valproic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid increases the expression of SLC51B			[17]
Bosentan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bosentan increases the expression of SLC51B			[18]
Cyclosporine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLC51B			[19]
Drug in Phase 3 Trial
Triclosan	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Triclosan inhibits the expression of SLC51B			[27]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A affects the expression of SLC51B			[28]
Drug in Phase 1 Trial
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quercetin inhibits the expression of SLC51B			[21]
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite inhibits the expression of SLC51B			[26]
Investigative Drug
Estrone sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estrone sulfate inhibits the transportation of Estrone sulfate by SLC51B (IC50 > 200 microM)			[]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Taurolithocholate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Taurolithocholate inhibits the transportation of Estrone sulfate by SLC51B (IC50 = 200 microM)			[]
Affected Drug/Substrate	Estrone sulfate	Modulation Type	Inhibition
Cell System	Oocytes-OSTalpha-OSTbeta
Lithocholic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lithocholic Acid increases the expression of SLC51B			[8]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	Human liver cells
Patented Pharmaceutical Agent
GW-4064	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	GW-4064 increases the expression of SLC51B			[20]
Regulation Mechanism	via enhancement of Bile acid receptor (NR1H4)			Transcription Factor Info
Cell System	Human adrenal cortex carcinoma cells (H295R)
Natural Product
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLC51B			[30]
Caffeine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Caffeine results in increased phosphorylation of SLC51B protein			[40]
Regulation Mechanism				Transcription Factor Info
Resveratrol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Plant Extracts co-treated with Resveratrol results in decreased expression of SLC51B mRNA			[53]
Regulation Mechanism				Transcription Factor Info
Traditional Medicine
Jinfukang	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Jinfukang increases the expression of SLC51B			[14]
Environmental toxicant
Resorcinol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Resorcinol inhibits the expression of SLC51B			[22]
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin inhibits the expression of SLC51B			[21]
Lead	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lead affects the methylation of SLC51B gene			[47]
Regulation Mechanism				Transcription Factor Info
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 increases the expression of SLC51B			[31]
Acute Toxic Substance
Fipronil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fipronil increases the expression of SLC51B			[25]
Carcinogen
Ethyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ethyl Methanesulfonate inhibits the expression of SLC51B			[23]
Benzo(a)pyrene	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC51B			[29]
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Arsenic results in decreased expression of SLC51B mRNA			[36]
Regulation Mechanism				Transcription Factor Info
Health and Environmental Toxicant
tris(1,3-dichloro-2-propyl)phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC51B			[24]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Perfluorooctane sulfonic acid increases the expression of SLC51B			[19]

References
1	Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OST/)
2	Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OST/). Mol Pharm. 2019 Jan 7;16(1):238-246.
3	Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G912-22.
4	The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes. Liver Int. 2015 Apr;35(4):1152-61.
5	Characterization and treatment of persistent hepatocellular secretory failure. Liver Int. 2015 Apr;35(4):1478-88.
6	Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
7	Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78.
8	Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
9	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203.
10	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
11	Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
12	Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46.
13	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
14	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
15	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
16	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
17	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
18	Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
19	Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. Arch Toxicol. 2020 May;94(5):1673-1686.
20	FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res. 2006 Jan;47(1):201-14.
21	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
22	A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
23	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
24	Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
25	Impact of Environmental Chemicals on the Transcriptome of Primary Human Hepatocytes: Potential for Health Effects. J Biochem Mol Toxicol. 2016 Aug;30(8):375-95.
26	Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
27	Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
28	Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134.
29	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
30	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
31	Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor. Toxicol Lett. 2011 Aug 28;205(2):146-53.
32	Validation of precision-cut liver slices to study drug-induced cholestasis: a transcriptomics approach. Arch Toxicol. 2017;91(3):1401-1412.
33	PCB congener specific oxidative stress response by microarray analysis using human liver cell line. Environ Int. 2010;36(8):907-17.
34	New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
35	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
36	Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023;43(8):1214-1224.
37	Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. Am J Respir Cell Mol Biol. 2011;45(3):470-9.
38	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172.
39	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
40	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022;449:116110.
41	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
42	Dataset on transcriptomic profiling of cholestatic liver injury induced by food additives and a cosmetic ingredient. Data Brief. 2021;38:107373.
43	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1124-30.
44	A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):268-74.
45	Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci. 2012 Apr;126(2):446-56.
46	Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions. Toxicol Sci. 2020;176(1):34-35.
47	Blood DNA methylation biomarkers of cumulative lead exposure in adults. J Expo Sci Environ Epidemiol. 2021;31(1):108-116.
48	In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of hydroxybutyrate (GHB) binding. Toxicol In Vitro. 2017;40:196-202.
49	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
50	Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. Toxicol Sci. 2015;146(2):363-73.
51	In vitro screening of understudied PFAS with a focus on lipid metabolism disruption. Arch Toxicol. 2024;98(10):3381-3395.
52	Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009;4(8):e6796.
53	One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69-82.
54	High-throughput, quantitative assessment of the effects of low-dose silica nanoparticles on lung cells: grasping complex toxicity with a great depth of field. BMC Genomics. 2015;16(1):315.
55	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
56	Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021;22(20).
57	Toxicogenomics of the flame retardant tris (2-butoxyethyl) phosphate in HepG2 cells using RNA-seq. Toxicol In Vitro. 2018;46:178-188.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence